Eprodisate |
| Catalog No.GC35999 |
L'eprodisate est un nouveau composé conÇu pour interférer avec les interactions entre les protéines amyloÏdogènes et les glycosaminoglycanes et ainsi inhiber la polymérisation des fibrilles amyloÏdes et le dépÔt des fibrilles dans les tissus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 21668-77-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues[1]. Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis[2].
[1]. Dember LM, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. [2]. Manenti L, et al. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach• Expert Opin Pharmacother. 2008 Aug;9(12):2175-80.
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *